Three Major RNA Drug Technology Pathways Explained: From Mechanisms to Future Trends

With the rapid advancement of nucleic acid biotechnology and precision medicine, RNA therapeutics are increasingly becoming one of the key directions in modern innovative drug development. Among them, antisense oligonucleotides (ASO), small interfering RNA (siRNA), and mRNA-based therapies represent three of the most clinically translatable technological pathways. By regulating gene expression or protein production at different biological levels, RNA therapies are creating new treatment possibilities for genetic disorders, cancer, and metabolic diseases.

Major Categories of Nucleic Acid Drugs

In today’s biopharmaceutical R&D landscape, nucleic acid drugs are typically classified according to their molecular type and level of biological action. Different technological approaches can function at multiple stages, including gene silencing, gene activation, or protein replacement, thereby forming diversified therapeutic strategies.

Key categories of nucleic acid therapeutics include:

● Antisense oligonucleotide (ASO) drugs: Suppress gene expression by modulating mRNA stability or pre-mRNA splicing

● RNA interference therapeutics (siRNA, shRNA): Induce degradation of target mRNA through the RNAi mechanism

● mRNA drugs: Deliver protein-encoding mRNA to enable in vivo protein expression

● miRNA/saRNA regulatory drugs: Modulate gene regulatory networks or enhance transcriptional activity

● RNA aptamers: Block signaling pathways by specifically binding to protein targets

This classification highlights that nucleic acid therapeutics are forming an integrated treatment platform spanning gene regulation, protein expression, and signal blockade, among which ASO, siRNA, and mRNA technologies remain the most established.

Mechanism of Antisense Oligonucleotides (ASO)

In the development history of RNA therapeutics, antisense oligonucleotides (ASOs) were among the earliest nucleic acid drugs to achieve clinical application. Their core feature lies in complementary binding to target mRNA sequences, enabling post-transcriptional regulation of protein expression. This mechanism provides new therapeutic solutions for diseases that are difficult to target with traditional small molecules or monoclonal antibodies.

⭐ Major mechanisms of ASO therapies include:

● Recruitment of RNase H to degrade target mRNA and reduce pathogenic protein synthesis

● Modulation of pre-mRNA splicing patterns, leading to altered protein isoform expression

● Blocking ribosome binding, thereby inhibiting translation

● Ability to function in both the nucleus and cytoplasm

Representative drugs such as Nusinersen and Inotersen have achieved significant clinical progress in rare genetic diseases, demonstrating the value of ASO technology in precise gene expression regulation.

Mechanism of Small Interfering RNA (siRNA)

With the in-depth understanding of RNA interference (RNAi) technology, siRNA therapeutics have become powerful tools for achieving efficient gene silencing. These molecules induce sequence-specific degradation of target mRNA, effectively shutting down disease-related gene expression pathways at the molecular level, and therefore show strong potential in chronic disease treatment.

⭐ Core mechanisms of siRNA therapies include:

● Cellular uptake followed by loading into the RNA-induced silencing complex (RISC)

● Guiding the complex to recognize and cleave complementary mRNA sequences

● Achieving sustained and efficient gene silencing effects

● Advanced delivery systems such as lipid nanoparticles (LNPs) or GalNAc conjugation enhance tissue targeting